Новости Антиподии
Feb. 2nd, 2022 05:06 pm![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
michaelkoloboffАвстралийский регулятор одобрил очередной шмурдяк.
https://www.tga.gov.au/sites/default/files/novavax-auspar.pdf
Идем на страницу 87, читаем Data limitations, охуеваем.
Для ленивых избранное:
- Data on vaccine efficacy to prevent asymptomatic infection are lacking.
- Data in frail elderly with unstable health conditions and co-morbidities are not
available.
- There are no data provided by the sponsor regarding Nuvaxovid efficacy against new
VOC, for example Omicron and Delta.
- Duration of protection of Nuvaxovid is uncertain due to limited follow up duration. In
Part one of Study 2019nCoV-101, immune response (IgG titre and neutralising
antibodies) gradually decreased through Day 189.
- No safety and efficacy data in immunocompromised patients or patients with
background autoimmune disease
- Short-term safety data may not provide information on rare AEs, risk of vaccine
associated enhanced disease (VAED) or vaccine-associated enhanced respiratory
disease (VAERD) as the antibodies wane over time, and there may be AEs that have a
long latency period including AEs of special interest
---
Сдется мне, вот так у них со всеми медикаментами. И не только в Авсралии.
https://www.tga.gov.au/sites/default/files/novavax-auspar.pdf
Идем на страницу 87, читаем Data limitations, охуеваем.
Для ленивых избранное:
- Data on vaccine efficacy to prevent asymptomatic infection are lacking.
- Data in frail elderly with unstable health conditions and co-morbidities are not
available.
- There are no data provided by the sponsor regarding Nuvaxovid efficacy against new
VOC, for example Omicron and Delta.
- Duration of protection of Nuvaxovid is uncertain due to limited follow up duration. In
Part one of Study 2019nCoV-101, immune response (IgG titre and neutralising
antibodies) gradually decreased through Day 189.
- No safety and efficacy data in immunocompromised patients or patients with
background autoimmune disease
- Short-term safety data may not provide information on rare AEs, risk of vaccine
associated enhanced disease (VAED) or vaccine-associated enhanced respiratory
disease (VAERD) as the antibodies wane over time, and there may be AEs that have a
long latency period including AEs of special interest
---
Сдется мне, вот так у них со всеми медикаментами. И не только в Авсралии.
no subject
Date: 2022-02-02 09:26 am (UTC)no subject
Date: 2022-02-02 09:34 am (UTC)no subject
Date: 2022-02-02 09:53 am (UTC)no subject
Date: 2022-02-02 10:28 am (UTC)no subject
Date: 2022-02-02 10:31 am (UTC)